前列腺癌是美国和欧洲男性最常见的非皮肤恶性肿瘤。寡转移性前列腺癌 (omPC) 尚无共识定义，通常被认为分为同步（从头）和异时（寡复发）两个亚组，并且可能包括转移性疾病负担较低的患者。总结流行病学、疾病定义同步、异时和混合亚型（即同步和异时或未定义类型）omPC 以及低负担疾病状态患者的临床试验和现实环境中的死亡率/生存结果以及治疗特征。我们搜索了 MEDLINE 和 Embase，以找到有关 omPC 流行病学、疾病定义、临床结果和治疗特征的出版物。对灰色文献来源（例如，ClinicalTrials.gov）进行了搜索以查找正在进行的试验。我们确定了 105 篇出版物。不同出版物和 omPC 亚型的疾病定义在病变数量和位置、所用影像类型以及寡转移疾病类型方面有所不同。大多数研究将 omPC 定义为五个或更少的转移病灶。有关 omPC 流行病学的数据有限。同步 omPC 队列与异时 omPC 队列相比，死亡率和总生存率往往更差。同步 omPC 队列的无进展生存期通常比异时 omPC 队列更长，但在较长时间点更相似。还提供了正在进行的针对 omPC 男性的各种局部、针对转移和全身治疗的临床试验总结。寡转移性疾病的定义取决于所使用的成像技术。 omPC 的流行病学数据很少。同步队列和异时队列之间的生存率不同，不同的治疗模式会导致不同的结果。我们期待并需要使用现代成像技术进行正在进行的临床试验。寡转移性前列腺癌 (omPC) 的定义因所使用的成像技术而异。不同的治疗模式会导致不同的结果。缺乏可靠的 omPC 流行病学数据。版权所有 © 2024。由 Elsevier B.V. 出版。

Prostate cancer is the most common noncutaneous malignancy among men in the USA and Europe. There is no consensus definition of oligometastatic prostate cancer (omPC), which is often considered in two subgroups, synchronous (de novo) and metachronous (oligorecurrent), and may include patients with a low metastatic disease burden.To summarize the epidemiology, disease definitions, mortality/survival outcomes, and treatment characteristics in both clinical trial and real-world settings among patients with synchronous, metachronous, and mixed-subtype (ie, synchronous and metachronous or undefined type) omPC, as well as low burden disease states.We searched MEDLINE and Embase to identify publications reporting on epidemiology, disease definitions, clinical outcomes, and treatment characteristics of omPC. Gray literature sources (eg, ClinicalTrials.gov) were searched for ongoing trials.We identified 105 publications. Disease definitions varied across publications and omPC subtypes on the number and location of lesions, type of imaging used, and type of oligometastatic disease. Most studies defined omPC as five or fewer metastatic lesions. Data on the epidemiology of omPC were limited. Mortality rates and overall survival tended to be worse among synchronous versus metachronous omPC cohorts. Progression-free survival was generally longer among synchronous than among metachronous omPC cohorts but was more similar at longer time points. A summary of ongoing clinical trials investigating a variety of local, metastasis-directed, and systemic therapies in men with omPC is also provided.Definitions of oligometastatic disease depend on the imaging technique used. Epidemiologic data for omPC are scarce. Survival rates differ between synchronous and metachronous cohorts, and heterogeneous treatment patterns result in varied outcomes. Ongoing clinical trials using modern imaging techniques are awaited and needed.Definitions of oligometastatic prostate cancer (omPC) vary depending on the imaging technique used. Different treatment patterns lead to different outcomes. Robust omPC epidemiologic data are lacking.Copyright © 2024. Published by Elsevier B.V.